News 2023-06-23
Dr. Angelo Maria Manzo of Porton Pharma Solutions Joins BOS Basel 2023, Spearheading Collaborations and Growth Opportunities
Dr. Angelo Maria Manzo, our esteemed Senior Business Development Manager at Porton Pharma Solutions Ltd., joins us at BOS Basel 2023!
Angelo’s deep industry knowledge and strategic vision are set to make a remarkable impact as he explores new collaborations, identifies growth opportunities, and expands our network.
Drop by Stand 17 to catch up with him during the 2-day event in Basel, Switzerland!
If you would like to preschedule a meeting, https://lnkd.in/eFzuWJBN
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
